New antiviral agents for the treatment of hepatitis C: ABT-450.

Abstract:

INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 - 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging. AREAS COVERED:Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented. EXPERT OPINION:Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.

authors

Carrion AF,Gutierrez J,Martin P

doi

10.1517/14656566.2014.889116

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

711-6

issue

5

eissn

1465-6566

issn

1744-7666

journal_volume

15

pub_type

杂志文章,评审
  • Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.

    abstract:INTRODUCTION:Postprandial hyperglycemia (PPHG) contributes to micro- and macro-vascular complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, particularly Indians and Chinese need agents to control the higher risk of uncontrolled ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070827

    authors: Joshi SR,Standl E,Tong N,Shah P,Kalra S,Rathod R

    更新日期:2015-01-01 00:00:00

  • Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.

    abstract:BACKGROUND:This subgroup analysis of STELLA-LONG TERM interim data explored the long-term safety and efficacy of ipragliflozin in non-elderly vs. elderly Japanese type 2 diabetes mellitus (T2DM) patients. RESEARCH DESIGN AND METHODS:STELLA-LONG TERM is an ongoing 3-year prospective surveillance study of Japanese T2DM ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1434145

    authors: Maegawa H,Tobe K,Tabuchi H,Nakamura I,Uno S

    更新日期:2018-03-01 00:00:00

  • Oral chemotherapy for the treatment of hepatocellular carcinoma.

    abstract:INTRODUCTION:Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). However, few agents have shown efficacy. It is thought that the efficacy of some agents might have resulted from the heterogeneity of tumors, insufficient dosages due to liver cirrhosis, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1479398

    authors: Yamamoto S,Kondo S

    更新日期:2018-06-01 00:00:00

  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Bipolar disorders: new approaches to therapy.

    abstract::This article reviews the evidence supporting different somatic treatment strategies in the acute and maintenance treatment phases of bipolar disorder. Bipolar affective disorder is a chronic disorder with a life time incidence of 0.3 - 1.5/100 [1]. Severe affective disorder is associated with a risk of completed suici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.4.601

    authors: Watson S,Young AH

    更新日期:2001-04-01 00:00:00

  • Miconazole, a pharmacological barrier to skin fungal infections.

    abstract:INTRODUCTION:Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic met...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.687047

    authors: Piérard GE,Hermanns-Lê T,Delvenne P,Piérard-Franchimont C

    更新日期:2012-06-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.

    abstract:INTRODUCTION:Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carb...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1512586

    authors: Wu G,Cheon E

    更新日期:2018-09-01 00:00:00

  • Docetaxel in ovarian cancer.

    abstract::Docetaxel, a semisynthetic taxane, is a potent inhibitor of cell replication and, similar to paclitaxel, promotes in vitro assembly of stable microtubules and, therefore, prevents the depolymerisation process. Docetaxel has a higher affinity for the tubulin subunit and is associated with a 100-fold greater phosphoryla...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.15.2719

    authors: Escobar PF,Rose PG

    更新日期:2005-12-01 00:00:00

  • Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.

    abstract:INTRODUCTION:Treatment of complicated intra-abdominal infections (cIAIs) is becoming increasingly difficult because of the widespread emergence of multidrug-resistant organisms. AREAS COVERED:In this review, we discuss the effectiveness of several new antibiotics for the treatment of cIAIs, including new β-lactamase i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1122756

    authors: Lin SY,Huang CH,Ko WC,Chen YH,Hsueh PR

    更新日期:2016-01-01 00:00:00

  • Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

    abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656561003592144

    authors: Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

    更新日期:2010-04-01 00:00:00

  • Olanzapine pamoate for the treatment of schizophrenia.

    abstract:INTRODUCTION:Nonadherence is still a major problem in the long-term treatment of schizophrenia. Long-acting injectable or depot atypical antipsychotics are associated with better maintenance. Olanzapine pamoate, available since 2010, is the second depot atypical antipsychotic. AREAS COVERED:This review covers data on ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.553193

    authors: Naber D

    更新日期:2011-03-01 00:00:00

  • Transdermal oxybutynin: a new treatment for overactive bladder.

    abstract::Overactive bladder has been successfully treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral oxybutynin has been effective in controlling urinary urge incontinence and in decreasing incontinence episodes, adverse events, particularly dry mouth, often cause patients to discontinue oral th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2315

    authors: Davila GW

    更新日期:2003-12-01 00:00:00

  • Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.

    abstract::Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2189

    authors: Mukherjee A,Dhadda AS,Shehata M,Chan S

    更新日期:2007-09-01 00:00:00

  • Pharmacogenomics of third-generation aromatase inhibitors.

    abstract:INTRODUCTION:Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.687721

    authors: Turkistani A,Marsh S

    更新日期:2012-06-01 00:00:00

  • An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.

    abstract:INTRODUCTION:The majority of patients with type 1 diabetes mellitus (T1DM) do not achieve glycemic targets. In addition, treatment with insulin is associated with increased risk for hypoglycemia and weight gain. Accordingly, there is an unmet need for new safe and effective glucose-lowering agents in this population. S...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1793961

    authors: Chatzopoulos G,Tziomalos K

    更新日期:2020-10-01 00:00:00

  • Pharmacological management of transient synovitis.

    abstract::Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.1.35

    authors: Sokoll KB,Helliwell P

    更新日期:2006-01-01 00:00:00

  • Intravesical therapy for bladder cancer.

    abstract:INTRODUCTION:Transurethral resection of bladder tumor (TURBT) is the gold standard initial diagnostic intervention for bladder cancer and provides diagnostic, therapeutic and prognostic benefit in non-muscle-invasive bladder cancer (NMIBC). However, TURBT alone is inadequate for optimal management of NMIBC, as patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1024656

    authors: Patel SG,Cohen A,Weiner AB,Steinberg GD

    更新日期:2015-04-01 00:00:00

  • The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children.

    abstract:OBJECTIVE:In a previous multicentre study including 129 HIV-infected children, non-adherence to antiretroviral therapy was detected in 16% of patients and was mainly related to psychosocial rather than clinical or demographic features. The aim of this study was to explore the evolving pattern of adherence and its deter...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1517/14656560903376178

    authors: Giannattasio A,Albano F,Giacomet V,Guarino A

    更新日期:2009-12-01 00:00:00

  • Pharmacological treatment for uterine leiomyosarcomas.

    abstract:INTRODUCTION:Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.985205

    authors: Gadducci A,Guerrieri ME

    更新日期:2015-02-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Current status in the pharmacological management of interstitial cystitis.

    abstract::Interstitial cystitis is a clinical condition occurring predominantly in women characterised by irritative voiding symptoms in the form of urinary frequency, urgency and pain. Patient symptoms have the potential to significantly affect quality of life, posing a challenge to some to perform activities of daily living. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.1967

    authors: Lukban JC

    更新日期:2003-11-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1378346

    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • Chemotherapeutic inhibitors in the treatment of prostate cancer.

    abstract:INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.852184

    authors: Deshmukh RR,Schmitt SM,Hwang C,Dou QP

    更新日期:2014-01-01 00:00:00

  • Current pharmacotherapy options for gastritis.

    abstract:INTRODUCTION:Gastritis is a broad term, which is used for different conditions by clinicians, endoscopists and pathologists. Classification strategies have led to more congruence between specialists. The histological evaluation of the gastric mucosa is mandatory for diagnosing and classifying gastritis. Main aetiologic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.747510

    authors: den Hollander WJ,Kuipers EJ

    更新日期:2012-12-01 00:00:00

  • Stiripentol and vigabatrin current roles in the treatment of epilepsy.

    abstract:INTRODUCTION:Stiripentol and vigabatrin are the two anticonvulsant drugs currently approved in severe infantile-onset epilepsies, respectively Dravet syndrome and infantile spasms. AREAS COVERED:For both, the indication was discovered by chance thanks to an exploratory study. Both demonstrated indisputable efficacy th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1161026

    authors: Chiron C

    更新日期:2016-06-01 00:00:00

  • Current and future therapies for the treatment of histamine-induced angioedema.

    abstract:INTRODUCTION:Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1282461

    authors: James C,Bernstein JA

    更新日期:2017-02-01 00:00:00

  • Update on pharmacotherapy of myoclonic seizures.

    abstract:INTRODUCTION:Myoclonic seizures are brief, involuntary muscular jerks arising from the central nervous system that can occur in different epilepsy syndromes, including idiopathic generalized epilepsies or the most severe group of epileptic encephalopathies. Valproate is commonly the first choice alone or in combination...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1280459

    authors: Striano P,Belcastro V

    更新日期:2017-02-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00